Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis

M. Sidhu; T. Mersaides; E. Liniker; D. Tate; G. Long; A. Nagrial; V. Kariyawasam; N. Sandanyake; R. Kefford; M. Carlino; V. Kwan

doi:10.1111/jgh.13094

Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis

M. Sidhu, T. Mersaides, E. Liniker, D. Tate, G. Long, A. Nagrial, V. Kariyawasam, N. Sandanyake, R. Kefford, M. Carlino, V. Kwan

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	139
Number of pages	1
Journal	Journal of Gastroenterology and Hepatology (Australia)
Volume	30
Issue number	Supplement s3
DOIs	https://doi.org/10.1111/jgh.13094
Publication status	Published - Sept 2015
Externally published	Yes

Access to Document

10.1111/jgh.13094

Cite this

Sidhu, M., Mersaides, T., Liniker, E., Tate, D., Long, G., Nagrial, A., Kariyawasam, V., Sandanyake, N., Kefford, R., Carlino, M., & Kwan, V. (2015). Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis. Journal of Gastroenterology and Hepatology (Australia), 30(Supplement s3), 139. https://doi.org/10.1111/jgh.13094

@article{a3e81d2cb96f4518995f099dff0a3b43,

title = "Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis",

author = "M. Sidhu and T. Mersaides and E. Liniker and D. Tate and G. Long and A. Nagrial and V. Kariyawasam and N. Sandanyake and R. Kefford and M. Carlino and V. Kwan",

year = "2015",

month = sep,

doi = "10.1111/jgh.13094",

language = "English",

volume = "30",

pages = "139",

journal = "Journal of Gastroenterology and Hepatology (Australia)",

issn = "0815-9319",

publisher = "Wiley-Blackwell, Wiley",

number = "Supplement s3",

}

Sidhu, M, Mersaides, T, Liniker, E, Tate, D, Long, G, Nagrial, A, Kariyawasam, V, Sandanyake, N, Kefford, R, Carlino, M & Kwan, V 2015, 'Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis', Journal of Gastroenterology and Hepatology (Australia), vol. 30, no. Supplement s3, pp. 139. https://doi.org/10.1111/jgh.13094

TY - JOUR

T1 - Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis

AU - Sidhu, M.

AU - Mersaides, T.

AU - Liniker, E.

AU - Tate, D.

AU - Long, G.

AU - Nagrial, A.

AU - Kariyawasam, V.

AU - Sandanyake, N.

AU - Kefford, R.

AU - Carlino, M.

AU - Kwan, V.

PY - 2015/9

Y1 - 2015/9

UR - https://doi.org/10.1111/jgh.13094

U2 - 10.1111/jgh.13094

DO - 10.1111/jgh.13094

M3 - Meeting abstract

SN - 0815-9319

VL - 30

SP - 139

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

IS - Supplement s3

ER -

Infliximab for the treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti PD-1) associated colitis

Access to Document

Other files and links

Cite this